Two-drug Regimens for HIV Treatment

Overview

Journal Lancet HIV

Specialty Infectious Diseases

Date 2022 Oct 29

PMID 36309038

Authors

Kevin M Gibas

Sean G Kelly

Jose R Arribas

Pedro Cahn

Chloe Orkin

Eric S Daar

Paul E Sax

Babafemi O Taiwo

Affiliations

Soon will be listed here.

Abstract

Combination therapy with three antiretroviral agents has been integral to successful HIV-1 treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary three-drug regimens have improved, even the newest therapies have potential adverse effects. The use of two-drug regimens is one way to reduce lifetime exposure to antiretroviral drugs while maintaining the benefits of viral suppression. Multiple large, randomised trials have shown the virological non-inferiority of certain two-drug regimens versus three-drug comparators, including adverse effect differences that reflect known profiles of the antiretroviral drugs in the respective regimens. Two-drug combinations are now recommended in treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1. Recommended two-drug regimens differ in their risks for, and factors associated with, virological failure and emergent resistance. The tolerability, safety, metabolic profiles, and drug interactions of two-drug regimens also vary by the constituent drugs. No current two-drug regimen is recommended for people with chronic hepatitis B virus as none include tenofovir. Two-drug regimens have increased options for individualised care.

Citing Articles

Prospective longitudinal assessment of Albumin-to-Creatinine ratio (ACR) in a clinical cohort of people living with HIV in Gaborone, Botswana.

Mosepele M, Kebotsamang K, Ponatshego P, Molebatsi K, Moshomo T, Mokgatlhe L BMC Infect Dis. 2025; 25(1):327.

PMID: 40055617 PMC: 11889908. DOI: 10.1186/s12879-025-10721-z.

Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses and .

Verwimp S, Wagoner J, Arenas E, De Coninck L, Abdelnabi R, Hyde J bioRxiv. 2025; .

PMID: 39896535 PMC: 11785157. DOI: 10.1101/2025.01.24.633564.

Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting....

Gouissi Anguechia D, Bouba Y, Ngoufack Jagni Semengue E, Kae A, Takou D, Ambe Chenwi C Viruses. 2025; 16(12.

PMID: 39772163 PMC: 11680099. DOI: 10.3390/v16121853.

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.

Short W, Patel P, Verdier G, Puga A, Vannappagari V, de Ruiter A Infect Dis Ther. 2024; 14(1):59-80.

PMID: 39652285 PMC: 11782740. DOI: 10.1007/s40121-024-01085-z.

Innate Immune Cell Functions Contribute to Spontaneous HIV Control.

Huber A, Baas F, van der Ven A, Dos Santos J Curr HIV/AIDS Rep. 2024; 22(1):6.

PMID: 39614998 PMC: 11608392. DOI: 10.1007/s11904-024-00713-0.

References

Orkin C, Bernal Morell E, Tan D, Katner H, Stellbrink H, Belonosova E . Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021; 8(11):e668-e678. DOI: 10.1016/S2352-3018(21)00184-3. View

Jaeger H, Overton E, Richmond G, Rizzardini G, Andrade-Villanueva J, Mngqibisa R . Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021; 8(11):e679-e689. DOI: 10.1016/S2352-3018(21)00185-5. View

Moreno S, Perno C, Mallon P, Behrens G, Corbeau P, Routy J . Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?. HIV Med. 2019; 20 Suppl 4:2-12. DOI: 10.1111/hiv.12716. View

Perez-Molina J, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M . Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label,.... J Antimicrob Chemother. 2016; 72(1):246-253. DOI: 10.1093/jac/dkw379. View

Trunfio M, Rugge W, Mighetto L, Vai D, Atzori C, Nigra M . Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. AIDS. 2020; 34(13):1899-1906. DOI: 10.1097/QAD.0000000000002601. View

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, DEttorre G, Antinori A . Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017; 72(4):1163-1171. DOI: 10.1093/jac/dkw557. View

Cahn P, Sierra Madero J, Arribas J, Antinori A, Ortiz R, Clarke A . Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2021; 36(1):39-48. PMC: 8654248. DOI: 10.1097/QAD.0000000000003070. View

Althoff K, Stewart C, Humes E, Zhang J, Gerace L, Boyd C . The shifting age distribution of people with HIV using antiretroviral therapy in the United States. AIDS. 2021; 36(3):459-471. PMC: 8795488. DOI: 10.1097/QAD.0000000000003128. View

Madeddu G, De Vito A, Cozzi-Lepri A, Cingolani A, Maggiolo F, Perno C . Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era. AIDS. 2021; 35(7):1103-1112. PMC: 9904439. DOI: 10.1097/QAD.0000000000002825. View

10.

van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses M . Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2020; 85(3):325-330. PMC: 7446981. DOI: 10.1097/QAI.0000000000002449. View

11.

Tan D, Rolon M, Figueroa M, Sued O, Gun A, Kaul R . Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial. PLoS One. 2019; 14(9):e0221653. PMC: 6730918. DOI: 10.1371/journal.pone.0221653. View

12.

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L . Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression.... J Antimicrob Chemother. 2013; 68(6):1364-72. DOI: 10.1093/jac/dkt007. View

13.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Le M . Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). J Antimicrob Chemother. 2020; 75(6):1611-1617. DOI: 10.1093/jac/dkaa035. View

14.

Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D . Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. Clinicoecon Outcomes Res. 2017; 9:173-179. PMC: 5338853. DOI: 10.2147/CEOR.S127097. View

15.

Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton E, Girard P . Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020; 382(12):1124-1135. DOI: 10.1056/NEJMoa1909512. View

16.

Smith G, Henry W, Podzamczer D, Masia M, Bettacchi C, Arasteh K . Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis. 2021; 8(9):ofab439. PMC: 8454521. DOI: 10.1093/ofid/ofab439. View

17.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J . Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type.... Clin Infect Dis. 2020; 71(8):1920-1929. PMC: 7643745. DOI: 10.1093/cid/ciz1243. View

18.

Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M . Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019; 6(9):e576-e587. DOI: 10.1016/S2352-3018(19)30149-3. View

19.

Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia M . Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020; 382(12):1112-1123. DOI: 10.1056/NEJMoa1904398. View

20.

Margolis D, Gonzalez-Garcia J, Stellbrink H, Eron J, Yazdanpanah Y, Podzamczer D . Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017; 390(10101):1499-1510. DOI: 10.1016/S0140-6736(17)31917-7. View